FDA: Food and Drug Administration Safety and Innovation Act (FDASIA) and Patient Focused Drug Development Read more
FDA Releases Final Risk Evaluation and Mitigation Strategies (REMS) for Extended Release/Long Acting Opioids Including a Prescriber Education Program Read more
FDA REMS: Blue Print for Prescriber Continuing Education Program for Extended Release-Long Acting Opioids Read more
The Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011: House Introduces Bill to Relieve FDA of Burdensome Conflict of Interest Quotas Read more
Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices or The Rothman’s Efforts to Undermine Public Health Read more